Currently, Hepatocellular Carcinoma (HCC) is one of the world's most challenging diseases in the field of oncology and is the most common form of liver cancer. In some cases, HCC can be treated through surgery and ablations but can be extended to a full transplant. Risk factors for HCC have been elucidated in previous years, linking hepatitis viruses, diabetes, and alcohol-dependent conditions to the pathogenesis of HCC. Given the prevalence of HCC in global populations (currently >800,000 new cases per year, and rising), there is a requirement to identify molecular targets in HCC and develop new therapeutic strategies to manage and treat HCCs.
New technologies and techniques, including gene sequencing, bioinformatics, and liquid biopsy, have helped identify molecular and genetic players involved in the development of HCC. As such, a comprehensive genetic/immune signature of HCC would be invaluable in the development of new therapeutics and treatment strategies, as well as early identification and management of HCC. There are currently various trials that implement a combination of already approved drugs to better the prognosis of patients suffering from HCC. There is, however, still room for improvement, and as our understanding of the various factors involved in HCC improves, so will the prognosis of patients suffering from HCC globally.
This Research Topic aims to highlight the molecular and genetic targets that lead to the progression of Hepatocellular Carcinoma. We welcome Original Research, Reviews, and other article types.
Currently, Hepatocellular Carcinoma (HCC) is one of the world's most challenging diseases in the field of oncology and is the most common form of liver cancer. In some cases, HCC can be treated through surgery and ablations but can be extended to a full transplant. Risk factors for HCC have been elucidated in previous years, linking hepatitis viruses, diabetes, and alcohol-dependent conditions to the pathogenesis of HCC. Given the prevalence of HCC in global populations (currently >800,000 new cases per year, and rising), there is a requirement to identify molecular targets in HCC and develop new therapeutic strategies to manage and treat HCCs.
New technologies and techniques, including gene sequencing, bioinformatics, and liquid biopsy, have helped identify molecular and genetic players involved in the development of HCC. As such, a comprehensive genetic/immune signature of HCC would be invaluable in the development of new therapeutics and treatment strategies, as well as early identification and management of HCC. There are currently various trials that implement a combination of already approved drugs to better the prognosis of patients suffering from HCC. There is, however, still room for improvement, and as our understanding of the various factors involved in HCC improves, so will the prognosis of patients suffering from HCC globally.
This Research Topic aims to highlight the molecular and genetic targets that lead to the progression of Hepatocellular Carcinoma. We welcome Original Research, Reviews, and other article types.